The flu season is approaching, YSB's "Supply Protection" drives sales growth
YSB ensured drug supply through a digital supply chain system during the peak flu season, with sales increasing by 36% year-on-year. Among them, the demand for Oseltamivir phosphate granules and capsules surged by 120%. The platform collaborated with multiple pharmaceutical companies to ensure stable supply of core drugs and optimized inventory management through a smart supply chain system. The self-owned brand "Le Yao Shi" saw a sales increase of over 135% for cold medications. In addition, YSB's immune small box supports rapid testing, enhancing the capacity of grassroots medical services
According to Zhitong Finance APP, recently, many regions across the country have experienced strong cold wave weather, and respiratory infectious diseases such as influenza have entered a high incidence period, putting grassroots medical institutions to the test in terms of both drug supply and medical services. The latest monitoring data from the National Influenza Center shows that influenza activity in southern provinces of China is on the rise, with an increase in the positive rate of the H3N2 influenza virus in some areas. The out-of-hospital pharmaceutical digital platform YSB (09885) is actively responding to grassroots medication needs by leveraging its digital supply chain system, providing effective support for strengthening the grassroots "supply defense line."
To ensure the stable supply of core drugs, YSB has established deep strategic partnerships with several domestic pharmaceutical companies, achieving full-category coverage of influenza treatment drugs such as Oseltamivir. At the same time, the platform uses a smart supply chain system to track changes in drug demand at grassroots terminals nationwide in real-time, enabling precise inventory management and further ensuring the stability of drug supply and distribution efficiency.
The high incidence season of influenza has also driven significant growth in the sales of related drugs on the platform. According to sales data disclosed by YSB, since October 2025, the overall sales scale of influenza-related drugs on the YSB platform has increased by 36% year-on-year, with particularly strong demand for commonly used clinical Oseltamivir phosphate granules and capsules, which saw a year-on-year sales surge of 120%. The platform's own brand "Le Yao Shi" cold medication has also achieved a year-on-year sales growth of over 135% due to its high cost-performance advantage.
In addition, YSB has empowered the diagnosis and treatment end through its "Spectrum Cabin" grassroots smart medical solution, further alleviating the pressure on grassroots prevention and control. According to YSB, its core product, the Immunity Small Box, supports "minute-level" rapid testing for influenza A and B after throat swab sampling, forming a good synergy with the drug supply chain business, with a month-on-month increase of over 60% in related testing numbers in October.
Some analysts believe that in the context of the overlapping high incidence of influenza and cold wave weather, the timely replenishment and precise allocation of grassroots medical resources have become key to prevention and control. YSB will further enhance its integrated service capability for drug supply and medical support by integrating upstream drug resources, mid-platform intelligent scheduling, and downstream smart testing services, assisting grassroots responses during this influenza season
